| A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis (NCT01186744) | Pfizer | 2010-09-01 |
| Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea (NCT01181570) | Innovaderm Research Inc. | 2010-09-01 |
| A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis (NCT01163253) | Pfizer | 2010-09-01 |
| Etanercept and Vascular Function in Psoriasis (NCT01989689) | Emory University | 2010-08-01 |
| Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice (NCT01147874) | Pfizer | 2010-08-01 |
| Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis (NCT01206387) | Sun Pharmaceutical Industries, Inc. | 2010-08-01 |
| Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis (NCT01206660) | Sun Pharmaceutical Industries, Inc. | 2010-08-01 |
| Psoriasis Inflammation and Systemic Co Morbidities (NCT01170715) | Rockefeller University | 2010-07-13 |
| Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis (NCT01119339) | Almirall, S.A. | 2010-07-01 |
| Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis (NCT01154101) | Sirtris, a GSK Company | 2010-06-07 |
| Regulatory T-cells in Psoriasis Patients as Targets for Therapy (NCT01233583) | University of Aberdeen | 2010-06-01 |
| Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis (NCT01139918) | Innovaderm Research Inc. | 2010-06-01 |
| Effect of Weight Loss on Psoriasis (NCT01137188) | University Hospital, Gentofte, Copenhagen | 2010-06-01 |
| The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis (NCT01139580) | Stiefel, a GSK Company | 2010-05-01 |
| The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis (NCT01088165) | Medical University of Vienna | 2010-05-01 |
| A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis (NCT01126619) | Abbott | 2010-05-01 |
| A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS) (NCT01090427) | Janssen Research & Development, LLC | 2010-05-01 |
| Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis (NCT00998829) | Pfizer | 2010-05-01 |
| Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life (NCT01169987) | AbbVie (prior sponsor, Abbott) | 2010-05-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis (NCT01094093) | AstraZeneca | 2010-04-11 |
| Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis (NCT01122095) | University of California, San Diego | 2010-04-01 |
| An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use (NCT01132235) | Florida Academic Dermatology Centers | 2010-04-01 |
| Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis (NCT01101100) | Bausch Health Americas, Inc. | 2010-04-01 |
| A Study in Participants With Moderate to Severe Psoriasis (NCT01107457) | Eli Lilly and Company | 2010-04-01 |
| A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis (NCT01096862) | Astellas Pharma Inc | 2010-03-23 |
| Improving Psoriasis Through Health and Well-Being (NCT01162252) | University of Rochester | 2010-03-01 |
| Golimumab Plus UVB-311nm in Psoriasis (NCT01088698) | Medical University of Graz | 2010-03-01 |
| CT 327 in the Treatment of Psoriasis Vulgaris (NCT00995969) | Creabilis SA | 2010-03-01 |
| Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database (NCT01081730) | Janssen Biotech, Inc. | 2010-02-09 |
| Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) (NCT01155570) | AbbVie (prior sponsor, Abbott) | 2010-02-01 |
| Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis (NCT01011621) | Mantecorp Industria Quimica e Farmaceutica Ltd. | 2010-02-01 |
| Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study (NCT01043393) | Sun Pharmaceutical Industries, Inc. | 2010-02-01 |
| Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis (NCT01356004) | Cairo University | 2010-01-01 |
| The Effect of Algae Dunaliella Bardawil on Psoriasis (2) (NCT01121081) | Sheba Medical Center | 2010-01-01 |
| Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis (NCT01077882) | University Hospital, Ghent | 2010-01-01 |
| A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks (NCT01098721) | Welichem Biotech Inc. | 2010-01-01 |
| Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept (NCT00992394) | Pfizer | 2010-01-01 |
| Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis (NCT01094717) | University of Utah | 2010-01-01 |
| Pioglitazone in Psoriasis- A Clinical and Molecular Study. (NCT01133561) | Cairo University | 2010-01-01 |
| Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab (NCT01435265) | Wake Forest University Health Sciences | 2010-01-01 |
| Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis (NCT00954915) | MacroGenics | 2009-12-01 |
| A Study for Adults With Plaque Psoriasis (NCT01018810) | Eli Lilly and Company | 2009-12-01 |
| Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis (NCT00975637) | Bausch Health Americas, Inc. | 2009-12-01 |
| On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection (NCT02376478) | Medical University of Vienna | 2009-12-01 |
| Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study (NCT01018134) | Sun Pharmaceutical Industries, Inc. | 2009-11-01 |
| Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis (NCT01019200) | George Washington University | 2009-11-01 |
| A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis (NCT00930384) | George Washington University | 2009-11-01 |
| Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis (NCT01029405) | Pfizer | 2009-11-01 |
| The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis (NCT01001208) | Amgen | 2009-11-01 |
| Premature Coronary Artery Disease (CAD) in Severe Psoriasis (NCT00893126) | University of Michigan | 2009-11-01 |
| Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315) (NCT00833053) | Merck Sharp & Dohme LLC | 2009-10-01 |
| A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis (NCT01008995) | Centocor, Inc. | 2009-10-01 |
| A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate (NCT01059773) | Janssen-Cilag International NV | 2009-10-01 |
| Prevalence of Sleep Disturbances in Psoriasis (NCT00895375) | Wake Forest University Health Sciences | 2009-10-01 |
| Safety and Efficacy of BFH772 in Psoriasis Patients (NCT00987870) | Novartis Pharmaceuticals | 2009-09-01 |
| Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments (NCT00967538) | Innovaderm Research Inc. | 2009-09-01 |
| Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab (NCT01077128) | AbbVie (prior sponsor, Abbott) | 2009-09-01 |
| Efficacy of Two Algae Formulations on Lipid Metabolism, Inflammation and Oxidative Stress Status in Individuals With Psoriasis (NCT01045395) | University of Manitoba | 2009-09-01 |
| Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis (NCT00971477) | University of California, Davis | 2009-08-01 |
| An Efficacy and Safety Study of PH-10 Aqueous Hydrogel for the Treatment of Plaque Psoriasis (NCT00941278) | Provectus Pharmaceuticals | 2009-07-01 |
| Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis (NCT00940862) | Innovaderm Research Inc. | 2009-07-01 |
| Mechanism of Action Study for Psoriasis (NCT00932113) | Tufts Medical Center | 2009-06-01 |
| Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis (NCT00937027) | Syntrix Biosystems, Inc. | 2009-06-01 |
| Systematic Review And Meta-Analysis Of Psoriasis Treatments. (NCT01425138) | Pfizer | 2009-06-01 |
| Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index (NCT00879944) | Northwestern University | 2009-05-01 |
| Peds Metabolic Syndrome in Psoriasis (NCT00930592) | Tufts Medical Center | 2009-04-01 |
| Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis (NCT00808223) | Astellas Pharma Inc | 2009-04-01 |
| Ustekinumab Plus UVB-311nm in Psoriasis (NCT00870285) | Medical University of Graz | 2009-03-01 |
| Study Evaluating Management of Patients With Moderate and Severe Psoriasis (NCT00894777) | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-03-01 |
| Exploratory Study of Natural Killer Cells in Human Skin (NCT00824889) | Assistance Publique Hopitaux De Marseille | 2009-02-01 |
| A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (NCT01177800) | Xian-Janssen Pharmaceutical Ltd. | 2009-02-01 |
| Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis (NCT00824980) | Immune Technologies & Medicine GmbH | 2009-01-01 |
| Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (NCT01704599) | Wayne State University | 2009-01-01 |
| Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3 (NCT00789880) | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-12-01 |
| A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis (NCT00747344) | Centocor, Inc. | 2008-12-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis (NCT00848055) | Boehringer Ingelheim | 2008-12-01 |
| Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life (NCT00823914) | Massachusetts General Hospital | 2008-12-01 |
| Fluphenazine Hydrochloride for Psoriasis (NCT00929578) | Tufts Medical Center | 2008-11-01 |
| Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis (NCT00782613) | Synvista Therapeutics, Inc | 2008-11-01 |
| A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis (NCT00778700) | Incyte Corporation | 2008-10-28 |
| Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis (NCT00800982) | University of California, San Francisco | 2008-10-01 |
| Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis (NCT00769184) | NeoStrata Company, Inc. | 2008-10-01 |
| Spanish Registry of Systemic Treatments in Psoriasis (NCT02075697) | Fundación Academia Española de Dermatología | 2008-10-01 |
| Moderate to Severe Plaque Psoriasis With Scalp Involvement (NCT00791765) | Amgen | 2008-10-01 |
| Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis (NCT00755196) | Pfizer | 2008-09-01 |
| Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis (NCT00763555) | Galderma R&D | 2008-09-01 |
| Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study) (NCT00773734) | Amgen | 2008-09-01 |
| Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet (NCT00735787) | Abbott | 2008-08-01 |
| Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis (NCT00715975) | Azidus Brasil | 2008-07-01 |
| Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis (NCT00678210) | Pfizer | 2008-07-01 |
| Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis (NCT00663052) | Pfizer | 2008-06-01 |
| Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings (NCT00708708) | Pfizer | 2008-06-01 |
| Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis (NCT00655564) | Wake Forest University | 2008-05-01 |
| Potential Research Study Participant Registry (NCT00710489) | University of California, Davis | 2008-05-01 |
| First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects (NCT01261767) | Novo Nordisk A/S | 2008-04-01 |
| A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis (NCT00679731) | AbbVie (prior sponsor, Abbott) | 2008-04-01 |
| Regulatory T Cells (Tregs) in Polymorphic Light Eruption (NCT00555178) | Medical University of Graz | 2008-03-01 |
| Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis (NCT00658788) | Galderma R&D | 2008-03-01 |
| Primary UVB-311nm and Adalimumab in Psoriasis Patients (NCT00638261) | Medical University of Graz | 2008-03-01 |
| Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis (NCT01039142) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2008-03-01 |